207 related articles for article (PubMed ID: 10715369)
1. Factors affecting continuation rates of DMPA.
Hubacher D; Goco N; Gonzalez B; Taylor D
Contraception; 1999 Dec; 60(6):345-51. PubMed ID: 10715369
[TBL] [Abstract][Full Text] [Related]
2. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
3. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
4. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
Keder LM; Rulin MC; Gruss J
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
[TBL] [Abstract][Full Text] [Related]
5. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
7. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru.
Hall P; Bahamondes L; Diaz J; Petta C
Contraception; 1997 Dec; 56(6):353-9. PubMed ID: 9494768
[TBL] [Abstract][Full Text] [Related]
8. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
9. Introduction of cyclofem once-a-month injectable contraceptive in Mexico.
Garza-Flores J; Moraks del Olmo A; Fuziwara JL; Figueroa JG; Alonso A; Monroy J; Perez M; Urbina-Fuentes M; Guevara SJ; Cedeno E; Barrios R; Ferman JJ; Medina LM; Velazquez E; Perez-Palacios G
Contraception; 1998 Jul; 58(1):7-12. PubMed ID: 9743890
[TBL] [Abstract][Full Text] [Related]
10. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women.
Cuong DT; My Huong NT
Contraception; 1996 Sep; 54(3):169-79. PubMed ID: 8899259
[TBL] [Abstract][Full Text] [Related]
11. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
12. DMPA use above the age of 35 in Thai women.
Taneepanichskul S; Reinprayoon D; Phaosavadi S
Contraception; 2000 Apr; 61(4):281-2. PubMed ID: 10899485
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
[TBL] [Abstract][Full Text] [Related]
14. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
15. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
16. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
[TBL] [Abstract][Full Text] [Related]
17. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
18. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
Paiva LC; Pinto-Neto AM; Faundes A
Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
[TBL] [Abstract][Full Text] [Related]
19. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate.
Canto De Cetina TE; Canto P; Ordoñez Luna M
Contraception; 2001 Mar; 63(3):143-6. PubMed ID: 11368986
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
